Enfusion Statistics
Total Valuation
Enfusion has a market cap or net worth of $837.03 million. The enterprise value is $805.62 million.
| Market Cap | 837.03M |
| Enterprise Value | 805.62M |
Important Dates
The next estimated earnings date is Tuesday, November 5, 2024, before market open.
| Earnings Date | Nov 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Enfusion has 93.21 million shares outstanding. The number of shares has increased by 17.83% in one year.
| Shares Outstanding | 93.21M |
| Shares Change (YoY) | +17.83% |
| Shares Change (QoQ) | +43.95% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 51.17% |
| Float | 41.73M |
Valuation Ratios
The trailing PE ratio is 258.80 and the forward PE ratio is 35.53.
| PE Ratio | 258.80 |
| Forward PE | 35.53 |
| PS Ratio | 4.05 |
| Forward PS | 3.48 |
| PB Ratio | 12.26 |
| P/FCF Ratio | 33.58 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 58.39, with an EV/FCF ratio of 33.94.
| EV / Earnings | 256.16 |
| EV / Sales | 4.28 |
| EV / EBITDA | 58.39 |
| EV / EBIT | 125.62 |
| EV / FCF | 33.94 |
Financial Position
The company has a current ratio of 4.15, with a Debt / Equity ratio of 0.20.
| Current Ratio | 4.15 |
| Quick Ratio | 3.81 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 0.80 |
| Debt / FCF | 0.76 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 6.62% and return on invested capital (ROIC) is 4.16%.
| Return on Equity (ROE) | 6.62% |
| Return on Assets (ROA) | 3.74% |
| Return on Capital (ROIC) | 4.16% |
| Revenue Per Employee | $170,917 |
| Profits Per Employee | $2,854 |
| Employee Count | 1,102 |
| Asset Turnover | 1.76 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Enfusion has paid $1.93 million in taxes.
| Income Tax | 1.93M |
| Effective Tax Rate | 26.53% |
Stock Price Statistics
The stock price has increased by +7.03% in the last 52 weeks. The beta is 0.91, so Enfusion's price volatility has been similar to the market average.
| Beta (5Y) | 0.91 |
| 52-Week Price Change | +7.03% |
| 50-Day Moving Average | 8.55 |
| 200-Day Moving Average | 8.93 |
| Relative Strength Index (RSI) | 73.30 |
| Average Volume (20 Days) | 328,258 |
Short Selling Information
The latest short interest is 1.90 million, so 2.04% of the outstanding shares have been sold short.
| Short Interest | 1.90M |
| Short Previous Month | 1.94M |
| Short % of Shares Out | 2.04% |
| Short % of Float | 4.55% |
| Short Ratio (days to cover) | 4.24 |
Income Statement
In the last 12 months, Enfusion had revenue of $188.35 million and earned $3.15 million in profits. Earnings per share was $0.04.
| Revenue | 188.35M |
| Gross Profit | 126.08M |
| Operating Income | 6.41M |
| Pretax Income | 5.67M |
| Net Income | 3.15M |
| EBITDA | 13.80M |
| EBIT | 6.41M |
| Earnings Per Share (EPS) | $0.04 |
Balance Sheet
The company has $34.45 million in cash and $18.00 million in debt, giving a net cash position of $16.45 million or $0.18 per share.
| Cash & Cash Equivalents | 34.45M |
| Total Debt | 18.00M |
| Net Cash | 16.45M |
| Net Cash Per Share | $0.18 |
| Equity (Book Value) | 89.42M |
| Book Value Per Share | 0.70 |
| Working Capital | 56.30M |
Cash Flow
In the last 12 months, operating cash flow was $27.54 million and capital expenditures -$3.80 million, giving a free cash flow of $23.74 million.
| Operating Cash Flow | 27.54M |
| Capital Expenditures | -3.80M |
| Free Cash Flow | 23.74M |
| FCF Per Share | $0.25 |
Margins
Gross margin is 66.94%, with operating and profit margins of 3.40% and 1.98%.
| Gross Margin | 66.94% |
| Operating Margin | 3.40% |
| Pretax Margin | 3.86% |
| Profit Margin | 1.98% |
| EBITDA Margin | 7.33% |
| EBIT Margin | 3.40% |
| FCF Margin | 9.12% |
Dividends & Yields
Enfusion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.83% |
| Shareholder Yield | -17.83% |
| Earnings Yield | 0.39% |
| FCF Yield | 2.98% |
Analyst Forecast
The average price target for Enfusion is $9.00, which is 0.22% higher than the current price. The consensus rating is "Sell".
| Price Target | $9.00 |
| Price Target Difference | 0.22% |
| Analyst Consensus | Sell |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Enfusion has an Altman Z-Score of 16 and a Piotroski F-Score of 5.
| Altman Z-Score | 16 |
| Piotroski F-Score | 5 |